Document is current
Any future updates will be listed below
-
Authors
Li, Daneng https://orcid.org/0000-0001-5330-7522
McCall, Linda M.
Hahn, Olwen M.
Hudis, Clifford A.
Cohen, Harvey J.
Muss, Hyman B.
Jatoi, Aminah
Lafky, Jacqueline M.
Ballman, Karla V.
Winer, Eric P.
Tripathy, Debu
Schneider, Bryan
Barry, William
Dickler, Maura N.
Hurria, Arti
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00601900 at ClinicalTrials.govDocuments that mention this clinical trial
Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study
https://doi.org/10.1007/s10549-018-4828-5
-
Funding
Funding for this research was provided by:
National Cancer Institute (UG1CA189823, U10CA180821, U10CA180882, P30CA033572, U10CA180790, U10CA180795, U10CA180820, U10CA180836, U10CA180838, U10CA180857, U10CA180858, U10CA180867, U10CA180888)
Genentech
Breast Cancer Research Foundation
- License Information
-
More Information
Article History
Received: 11 May 2018
Accepted: 18 May 2018
First Online: 22 May 2018
Compliance with ethical standards
:
: Debu Tripathy has received remuneration from Novartis and serves in a consultant/advisory role for Novartis, Pfizer, and Nektar. Maura N. Dickler serves in a consultant/advisory role for Genentech/Roche, Pfizer, Novartis, Eli Lilly, AstraZeneca, TapImmune, and GI Therapeutics. Arti Hurria serves in a consultant/advisory role for Pierian Biosciences and MJH Healthcare Holdings, LLC and has received funding from Celgene and Novartis.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Each participant signed an IRB-approved, protocol-specific informed consent document in accordance with federal and institutional guidelines.
